Mutants of igf binding proteins and methods of production of antagonists thereof
CA 2449290 A1 · Owner: Lang, Kurt · Inventors: Huber, Robert; Schumacher, Ralf; Zeslawski, Wojciech
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides a crystal suitable for X-ray diffraction comprising a complex of insulin-like growth factor I or II (IGF) and a polypeptide consisting of the amino acids 39-91 of IGFBP-1 the amino acids 55-, 107 of IGFBP-2, the amino acids 47-99 of IGFBP-3 the amino acids 39-91 of , IGFBP-4, the amino acids 40-92 of IGFBP-5 or the amino acids 40-92 of IGFBP-6 , or a fragment thereof consisting at least of the 9th to 12th cysteine of IGFBP- 1, IGFBP-2, IGFBP-3, IGFBP-4, or IGFBP-5 or at least of the 7th to 10th cysteine of IGFBP-6; methods for the determination of the atomic coordinates of such a crystal; IGFBP mutants with enhanced binding affinity for IGF-I and/or …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 5, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 5, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 5, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.